LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Generation Hematology Analyzer Introduced

By LabMedica International staff writers
Posted on 04 Jul 2017
Print article
Image: The next-generation Alinity hq hematology analyzer (Photo courtesy of Abbott Diagnostics).
Image: The next-generation Alinity hq hematology analyzer (Photo courtesy of Abbott Diagnostics).
Hematology is a medical specialty dedicated to studying the physiology of blood, and the cause, diagnosis, treatment, and prevention of diseases related to blood. In diagnostics testing, hematology tests look at blood composition, which includes the identification and quantification of different types of blood cells.

The Alinity hq analyzer (Abbott, Abbott Park, IL, USA) for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer is the first in the Alinity hematology series of instruments to be commercially released, and is part of the planned integrated hematology system designed to address the productivity needs of the high-volume laboratory. The Alinity hq was built from the ground up to help solve every day operational challenges and anticipated future needs for high-volume laboratories.

Some unique capabilities of the Alinity hq system include: Innovative, advanced optical technology combined with robust algorithms to handle normal and pathological samples. Design features that are intended to reduce manual steps and minimize errors, improve confidence in data and allow for uninterrupted operation and scalable, modular design to customize configurations to better serve a broad spectrum of laboratories.

As part of the Alinity family of harmonized systems, the Alinity hq analyzer has an intuitive user interface with iconography, color coding and reporting features shared by all Alinity instruments. The Alinity family also uses a common method for sample loading and reagent management, which helps laboratories simplify technician training. The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics.

Luis de Luzuriaga, divisional vice president and general manager for Abbott’s hematology business, said, “The Alinity hq launch is a key milestone for Abbott’s hematology business unit. Abbott is leading the way to providing a more efficient, complete laboratory solution that no competitor in the industry can match. With the Alinity family of harmonized systems, Abbott aims to simplify diagnostics testing across laboratory disciplines and help our customers improve patient outcomes.”

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.